The aftermath of acute pulmonary embolism: approach to persistent functional limitations

Boon, G.J.A.M.

12

Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in post-PE syndrome

G.J.A.M. Boon, S.M.J. Janssen, S. Barco, H.J. Bogaard, W. Ghanima, L.J.M. Kroft,
L.J. Meijboom, M.K. Ninaber, E.J. Nossent, M.A. Spruit, P. Symersky, H.W. Vliegen,
A. Vonk Noordegraaf, M.V. Huisman, B. Siegerink, J.J. Abbink, F.A. Klok

ABSTRACT

Background: The Post-Pulmonary Embolism Syndrome (PPES) comprises heterogeneous entities, including chronic thromboembolic disease with/without pulmonary hypertension (CTEPH/CTEPD), and deconditioning. We aimed to assess underlying physiological determinants of PPES, and efficacy and safety of rehabilitation training in these patients.

Methods: 56 consecutive PE patients with persistent dyspnea and/or functional limitations despite ≥3 months of anticoagulation underwent standardized diagnostic work-up including exercise testing as part of routine practice. All diagnostic (imaging and cardiopulmonary function) tests were interpreted by a core group of experienced clinicians. A subgroup of patients without CTEPH or other treatable conditions was referred for a 12-week personalized rehabilitation program, studying changes in physical condition and patient-reported outcome measures.

Results: Persistent vascular occlusions were observed in 21/56 patients (38%) and CTEPH was confirmed in ten (18%). Regarding those without CTEPH, impaired cardiopulmonary responses were evident in 18/39 patients with available CPET data (46%), unrelated to chronic thrombi. Rehabilitation was completed by 27 patients after excluding 29 (patients with CTEPH or treatable comorbidities, refusal, ineligibility, or training elsewhere). Training intensity, PE-specific quality of life (PEmb-QoL) and fatigue (CIS) improved with a median difference of 20W (p=0.001), 3.9 points (p<0.001) and 16 points (p=0.003), respectively. Functional status (Post-VTE Functional Status Scale) improved ≥1 grade in 18 (67%) patients, and declined in one (3.7%).

Conclusions: Our findings suggest that abnormal cardiopulmonary responses to exercise are common in patients with PPES and are not limited to those with chronic thrombi. Offering pulmonary rehabilitation to patients not treated otherwise seems safe and promising.

INTRODUCTION

After acute pulmonary embolism (PE), up to half of patients report persistent dyspnea and/or functional limitations despite adequate anticoagulant treatment.[1-6] The so-called Post-PE Syndrome (PPES) is characterized by a combination of abnormalities in echocardiographic parameters of right ventricular function, pulmonary artery hemodynamics and impaired gas exchange with increased dead-space ventilation at rest or during exercise, all possibly caused by the persistent thrombotic obstruction of the pulmonary arteries.[7-11] The most severe presentation of PPES is chronic thromboembolic pulmonary hypertension (CTEPH), with a 2-4% incidence among PE survivors.[12] Even if pulmonary artery pressures at rest are normal in the presence of persistent perfusion defects, a relatively high pulmonary vascular resistance, reduced right ventricular contractile reserve and increased dead-space ventilation may account for debilitating exertional dyspnea, also referred to as chronic thromboembolic pulmonary disease (CTEPD).[13-16] Etiologies explaining persistent complaints in patients without persistent perfusion defects include chronic right ventricular impairment, deconditioning and/or pre-existing comorbidities.[5,17-20] Depressive disorders, fear for potential complications or recurrences, and post-thrombotic panic syndrome further contribute to long-term functional impairment, which may lead to physical inactivity, subsequent deconditioning and a downward spiral as result.[21,22] Altogether, PPES is associated with decreased quality of life, unemployment and increased utilization of healthcare resources, although the underlying physiological determinants are largely unknown.[19,23,24]

Curative treatment for CTEPH is available, preferably pulmonary endarterectomy (PEA), whereas the optimal management of other forms of the PPES is not well established.[25] Small studies have shown promising results of PEA or balloon pulmonary angiography (BPA) in patients with CTEPD, but this is currently not the standard of care.[26-29] Although only few experience is available for pulmonary rehabilitation in patients with PPES, small studies do suggest positive effects on exercise capacity and quality of life in both PE patients [30-35] and those with CTEPH.[36-40] In the setting of other acute and chronic cardiopulmonary conditions e.g. coronary heart disease, chronic obstructive pulmonary disease (COPD), and interstitial lung disease, cardiac and/or pulmonary rehabilitation programs are routinely offered because of established reduction of cardiovascular mortality and morbidity, as well as improvement in quality of life, symptoms and exercise capacity.[41,42] We hypothesized that a personalized rehabilitation program may also improve functional status in patients with PPES.

In this study, we studied the underlying determinants of persistent complaints in patients with PPES, and aimed to get insight into the efficacy and safety of an outpatient

12

pulmonary rehabilitation program in patients with PPES in whom CTEPH and CTEPD suitable for PEA or BPA were ruled out.

METHODS

Study design and patients

This observational cohort study is a description of routine care. We prospectively followed all consecutive patients with imaging confirmed acute PE [43,44] referred to the 'post-PE syndrome clinic' of the Leiden University Medical Center (LUMC) between May 2017 and May 2019.[45] Firstly, in this dedicated clinic, adult PE patients with persistent moderate-to-severe dyspnea (modified Borg scale ≥3 at rest) and/or patient-reported relevant functional limitations despite adequate anticoagulation for at least 3 months were subjected to a standardized diagnostic work-up. Secondly, a subgroup of these patients that were not subjected to specific CTEPH/CTEPD treatment and did not have underlying comorbidities explaining their persistent symptoms, were invited to follow a post-PE-specific pulmonary rehabilitation program in an expertise center for specialist medical rehabilitation care (Basalt, Leiden, the Netherlands).

The local Ethics Committees of both LUMC and Basalt waived the need for informed consent because of the observational design of this study. All patients were actively informed of the intention to use the results and outcome of the dedicated clinic for scientific purposes and we have explicitly offered all patients to opt out. None objected to the use of anonymized data.

Objectives

The primary objectives of this study were: 1) to evaluate the underlying physiological determinants of exertional dyspnea in all patients referred to our 'post-PE syndrome clinic'; and 2) to get insight in the safety and efficacy of a rehabilitation program on training intensity, and patient-reported outcome measures in a subgroup of patients in whom CTEPH and CTEPD suitable for PEA or BPA were ruled out after standardized diagnostic work-up.

Procedures

1. Diagnostic work-up

This includes routine blood testing, resting echocardiography, computed tomography pulmonary angiography (CTPA) with subtraction perfusion mapping, cardiopulmonary exercise test using a stationary cycle ergometer (CPET), and pulmonary function test, if relevant followed by invasive right heart catheterization (RHC), ventilation/perfusion

imaging and/or pulmonary angiography.[46] The baseline test results were discussed in a multidisciplinary team of pulmonary hypertension experts, including cardiologists, pulmonologists, rheumatologists and vascular medicine specialists. Patients with (suspected) CTEPH or CTEPD potentially suitable for PEA or BPA were referred to the VU University Medical Center (CTEPH expertise center) for appropriate treatment. CTEPH was established if the following strict diagnostic criteria were met: 1) ≥1 mismatched segmental perfusion defect demonstrated by ventilation/perfusion (V/Q) scanning after ≥3 months of adequate therapeutic anticoagulation; 2) mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest measured by RHC; *and* 3) pulmonary artery wedge pressure (PAWP) ≤15 mmHg.[46] In case a treatable comorbidity was found, e.g. asthma, interstitial lung disease or left heart failure, treatment optimization was provided by the relevant medical specialist of the multidisciplinary team.

2. Rehabilitation program

The 12-week outpatient rehabilitation program in the previously mentioned subgroup was based on the Official ATS/ERS Statement: Key Concepts and Advances in Pulmonary Rehabilitation.[42] Patients participated in twice-weekly sessions of 90 minutes of supervised exercise training and, after two weeks, supplemented with one unsupervised training at home (**Appendix A**). During the supervised sessions, patients performed 30 to 40 minutes of endurance exercise, and 30 minutes of strength exercises. The endurance training was performed on a stationary cycle ergometer and/or a treadmill, and comprised endurance and/or interval exercise. According to current guidelines, each training was targeted at 70 to 80% of patients' individual maximum heart rate, which was routinely checked by the physiotherapist supervising the training.[42,47] When patients were over- or underperforming, if tolerable, this was corrected by adjusting the workload of the training in order to acquire the targeted heart rate. Strength training was aimed at either improving absolute muscle strength or improvement in muscle endurance using medical fitness equipment. For improvement of strength, patients trained at 75% of their one repetition maximum (1RM), performing 3 series of 8 repetitions. When training muscle endurance, 2 series of 15 repetitions at 65% of the 1RM were performed. Concerning the third training each week performed at home, patients were instructed to reach the same intensity as they did in the supervised training sessions. Additional counselling was tailored to the individual patient's needs and included support by a psychologist, dietician, occupational therapist or social worker including smoking cessation counselling if relevant (**Appendix A**).

12

Measurements

1. Diagnostic work-up

An incremental symptom-limited CPET was performed, if possible along with arterial blood sampling. Individual CPET results were used to evaluate cardiopulmonary responses to exercise in PPES according to the ATS/ACCP Statement and Wasserman's algorithms, particularly concerning presence of respiratory gas exchange, ventilatory efficiency and abnormal dead-space ventilation. Typical patterns of impaired (i.e. insufficient) cardiopulmonary responses to exercise are shown in **Table 1**.[48,49] Evaluation of results was done by 2 independent researchers (GJAMB and MKN). Parameters collected throughout the test include: oxygen uptake (VO2), heart rate (HR), minute ventilation (VE), O2 pulse (VO2/HR), anaerobic threshold (AT, determined using the V-slope method), carbon dioxide production (VCO2), arterial oxygen saturation, ventilatory equivalents for carbon dioxide (VE/VCO2, point measure at AT), dead-space fraction (Vd/Vt), alveolar-arterial gradient (p(A-a)O2). Since maximum voluntary ventilation (MVV) was not directly measured, it was calculated using the following prediction equation (FEV1 x 40).[50] All parameters are obtained during peak exercise except for AT and VE/VCO2 at AT, reference values from the ATS-ACCP Statement on CPET were used.[49]

Table 1: Typical patterns of insufficient cardiopulmonary responses to exercise, useful for determining causes of exercise limitation

	Cardiovascular impairment*	Respiratory impairment[#]	Pulmonary vascular impairment[^]
Peak VO2	Reduced	Reduced	Reduced
Peak HR	Normal/slightly reduced	Reduced	Normal
Peak O2 pulse	Reduced/plateau	Normal	Reduced/plateau
Peak SpO2	Normal/drop	Normal/drop	Drop
VE/MVV	Normal	Increased	Normal
VE/VCO2 at AT	Increased	Increased	Increased
Vd/Vt	Increased	Increased	Increased
P(A-a)O2	Normal/increased	Increased	Increased

Note: adapted from references [48,49,51,52]. Maximum or peak cardiopulmonary responses except for VE/VCO2 at AT.

* Cardiovascular impairment refers to left ventricular failure, congestive heart disease and myocardial ischemia.

[#] Respiratory impairment refers to parenchymal disease including obstructive and restrictive lung diseases and lung disease with impaired peripheral oxygenation.

[^] Pulmonary vascular impairment refers to diseases with increased dead-space ventilation.

Abbreviations: CPET, cardiopulmonary exercise testing; VO2, oxygen uptake, pred, predicted; HR, heart rate; O2 pulse, oxygen consumed per heart rate; SpO2, arterial oxygen saturation; VE/MVV, ventilatory reserve; VE/VCO2, ventilatory equivalent for carbon dioxide; AT, anaerobic threshold; Vd/VT, dead-space fraction; p(A-a)O2, alveolar-arterial gradient; V/Q, ventilation/perfusion; Y, yes.

Pulmonary function testing comprised spirometry, body plethysmography, and single breath carbon monoxide diffusion.[53] Echocardiographic explanations of persistent dyspnea were classified as signs of pulmonary hypertension, signs of diastolic or systolic dysfunction, valvular heart disease, and/or cardiomyopathy. CTPA with iodine perfusion mapping was performed to assess the presence of residual thrombotic lesions and/or persistent perfusion defects on CT scanners with at least 64 slices and a reconstructed slice thickness of 1 to 3 mm.

2. Rehabilitation program

Training intensity (defined as peak power output in Watts) was used as a surrogate for measuring the effect of rehabilitation since maximal workload as determined by CPET was not available at discharge. Peak power output was assessed during the first and last training sessions of the rehabilitation program. Questionnaires on self-reported quality of life (PEmb-QoL, PE-specific Quality of Life), fatigue (CIS, Checklist Individual Strength-Fatigue), and anxiety and depression (HADS, Hospital Anxiety and Depression Scale) were completed before start and after completion of the rehabilitation program.[54-57] Two independent researchers (SMJJ and GJAMB) evaluated functional status before and after the rehabilitation program for each participant and assigned a grade on the Post-VTE Functional Status (PVFS) Scale (**Appendix B**).[58-60] Subsequently, the degree of improvement or decline was evaluated, both at group and at individual level. Safety issues were closely monitored and reported 1) during a specific training session (i.e. syncope or arrhythmia); or 2) while completing the rehabilitation program (i.e. symptomatic recurrent venous thromboembolism, new cardiopulmonary diagnoses, death). Data on relevant patient demographics, the PE diagnosis, comorbidities, relevant outpatient follow-up details, results of the standardized diagnostic testing and details of the rehabilitation program were extracted from the medical charts by the treating physician.

Statistical analysis

Baseline characteristics are described as mean with standard deviation (SD), median with interquartile range (IQR), or numbers with proportions if appropriate. Comparison of variables before start and after completing the rehabilitation program was performed using the paired t-test or Wilcoxon matched-pairs signed rank test where appropriate. Measures of odds ratio (OR) are reported as point estimates with corresponding 95% confidence intervals (95% CI). All statistical tests were performed using SPSS Statistics software (version 25.0, IBM) and visualisation was conducted using SankeyMATIC (http://sankeymatic.com/build/). Validated minimal clinically important differences (MCIDs) of the individual tests and questionnaires have been used if available to

12

determine relevant outcomes when comparing results before and after completing the rehabilitation program.[61,62]

RESULTS

Baseline

The baseline characteristics of 56 patients referred to the 'post-PE syndrome clinic' after adequate anticoagulant treatment are displayed in **Table 2**, all of whom underwent standardized diagnostic work-up (**Fig 1**)**.** Of the total study population, cardiopulmonary responses were evaluated in 45 patients after excluding those with alternative diagnoses (N=3) and those whom refused to undergo a CPET (N=8). A total

Table 2: Baseline characteristics of the patients with Post-PE Syndrome subjected to the standardized diagnostic work-up

	All PE patients (N=56)
Age at PE event (years, mean ±SD)	54 (14)
Male sex (N, %)	22 (39%)
BMI (kg/m^2, mean ±SD)	29 (6.3)
Located in main pulmonary artery	14 (25%)
Unprovoked PE (N, %)	29 (52%)
Previous VTE (N, %)	15 (27%)
Pre-existing comorbidity (N, %)	
COPD / asthma	10 (18%)
Diabetes mellitus	3 (5.4%)
Coronary artery disease	2 (3.6%)
Heart failure	2 (3.6%)
Active malignancy	1 (1.8%)
Smoking status (N, %)	
Never	30 (54%)
Quit smoking	19 (34%)
	Pack years (mean ±SD): 16 (11)
Currently smoking	7 (13%)
	Pack years (mean ±SD): 35 (18)
Type of anticoagulant treatment (N, %)	
DOAC	27 (48%)
VKA	26 (46%)
LMWH	2 (3.6%)
Indefinite anticoagulant treatment (N, %)	34 (61%)

Abbreviations: SD, standard deviation; BMI, body mass index; VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant.

Figure 1: Flowchart of study patients

Note: Study part 1: diagnostic work-up with CTPA and echocardiography was performed in all patients, but CPET allowing cardiopulmonary response evaluation data was only available for 45 patients. The presence/absence of CTEPH and the presence/absence of persistent vascular occlusions are shown, with corresponding CPET findings. Study part 2: the rehabilitation program was completed by 27 patients.

Abbreviations: PPES, Post-PE Syndrome; CPET, cardiopulmonary exercise test; CTEPH, chronic thromboembolic pulmonary hypertension.

12

of 27 patients participated in the PE-specific rehabilitation program after the exclusion of 22 patients (CTEPH, N=10; alternative diagnoses, N=3; ineligibility to participate, N=3; or lack of motivation, N=6). Rehabilitation was performed elsewhere because of patient preferences in 7 patients.

Diagnostic work-up

Median time from PE diagnosis till referral was 6.4 months (IQR 4.3-31). A total of 16 of 56 (29%) patients had at least one pre-existing comorbidity, including 10 patients (18%) having COPD/asthma and 3 (5.4%) having diabetes mellitus. After completing standardized diagnostic work-up in the total population, CTEPH was confirmed by right heart catheterization (RHC) in ten patients (18%). Median time between PE and CTEPH diagnosis was 4.5 months (IQR 3.0-11). Echocardiography revealed signs of PH in three other patients, whom had no PH at invasive measurement by RHC, and diastolic dysfunction was observed in two. In addition to CTEPH patients, unresolved thrombi (according to CTPA assessment) and/or persistent perfusion defects (based on V/Q scan) were present in 21 patients (38%), none of whom were treated with PEA or BPA. Of the remaining 25 patients, previously unknown conditions were considered to be the primary etiology of the persistent dyspnea in three (5%) patients: iron deficiency anemia in one and interstitial lung disease in two patients.

Exercise-induced cardiopulmonary response evaluation

During peak exercise, CPET revealed a median power output of 120 Watts (IQR 80 to 180) with a mean heart rate of 146/min (SD 24) and a median breathing frequency of 35/min (IQR 31 to 43) (**Table 3**). Mean peak VO2 was 1683 (SD 785) ml/min and was reduced (<85% of predicted) in 19 of 45 patients (42%). Mean minute ventilation at peak exercise consisted of 71 L/min (SD 27), which is 61% of MVV (SD 0.16). Unresolved thrombi and/or persistent perfusion defects were present in 24 of 45 patients (53%) including 6 with CTEPH. Of 39 non-CTEPH cases, either pulmonary vascular or cardiovascular impairment was observed during incremental exercise in 21 (54%) patients, of whom 11 (52%) had residual vascular occlusions (odds ratio 1.7, 95%CI 0.48 to 6.2). Pulmonary vascular impairment was the exclusive underlying determinant in six (15%) patients and cardiovascular impairment in one (2.6%). All CTEPH patients had either signs of pulmonary vascular or cardiovascular impairment. Parenchymal lung disease was ruled out as primary etiology in any of these study patients. Mild respiratory impairment, however, contributed partially in two patients, i.e. asthma and interstitial lung disease (**Table 3**).

Table 3: Cardiopulmonary responses to exercise in PPES patients

	Peak VO2 (% of pred)	Peak HR (% of pred)	Peak O2 pulse (% of pred)	Peak SpO2*	VE/MVV x 100	VE/VCO2 at AT	Peak Vd/VT	Peak p(A-a)O2 (kPa)	Unresolved thrombi and/or persistent perfusion defects[#]	Interpretation cardiopulmonary response
No. 1	35	68	52	93	47%				Y: CTEPH	Cardiovascular impairment
No. 2	51	88	58	92	45%	46,6			Y: CTEPH	Pulmonary vascular and cardiovascular impairment
No. 3	69	99	70	93	64%	53,2			Y: CTEPH	Pulmonary vascular and cardiovascular impairment
No. 4	65	73	89	94	55%	33,5			Y: CTEPH	Cardiovascular impairment
No. 5	90	98	92	89	54%	38,3	42	6,65	Y: CTEPH	Pulmonary vascular impairment
No. 6	47	91	52	81	63%	52,3			Y: CTEPH	Pulmonary vascular and cardiovascular impairment
No. 7	62	86	72	95	72%				Y	Cardiovascular impairment
No. 8	74	93	80	82	74%	38,1			Y	Pulmonary vascular and cardiovascular impairment
No. 9	115	89	128	99	65%	24,8	14	3,38	Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 10	99	103	96	95	68%	33,8		5,54	Y	Pulmonary vascular impairment
No. 11	129	93	136	95	67%	27			Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 12	93	100	101		94%	48,2	23		Y	Pulmonary vascular impairment (combined with a component interstitial lung disease)
No. 13	78	80	98	99	44%	25,4			Y	Cardiovascular impairment
No. 14	61	62	87	100	46%	38,3			Y	Pulmonary vascular and cardiovascular impairment
No. 15	93	101	92	97	80%	33,5	18	4,22	Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 16	101	103	98	98	73%	29,2			Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 17	101	98	104	99	54%		28	4,1	Y	Pulmonary vascular impairment

12

Table 3: Cardiopulmonary responses to exercise in PPES patients *(continued)*

	Peak VO2 (% of pred)	Peak HR (% of pred)	Peak O2 pulse (% of pred)	Peak SpO2*	VE/MVV x 100	VE/VCO2 at AT	Peak Vd/VT	Peak p(A-a)O2 (kPa)	Unresolved thrombi and/or persistent perfusion defects#	Interpretation cardiopulmonary response
No. 18	74		89		48%	28,9	34		Y	Pulmonary vascular and cardiovascular impairment
No. 19	97	99	95	99	72%	26,6			Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 20	79	118	67	97	69%	40,6	34	6,09	Y	Pulmonary vascular and cardiovascular impairment
No. 21	97	109	87	91	85%	32,7			Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 22	101	77	131	99	61%	27,1			Y	No cardiovascular, respiratory or pulmonary vascular impairment
No. 23	96	84	114	96	64%	37	30	5,93	Y	Pulmonary vascular impairment
No. 24	62		82						Y	Cardiovascular impairment
No. 25	117	89	132	97	50%	25,4	15	2,12	-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 26	95	94	101	100	72%	24,8	25		-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 27	119	73	178	99		29,9			-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 28	83	94	74	100		27,8			-	Cardiovascular impairment^
No. 29	95	78	121	100	53%	31,7			-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 30	103	79	131	99	62%	29,5	23	3,1	-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 31	85	70	120	100	53%	34,4			-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 32	89	97	91	98	107%	35,4	31	2,79	-	Pulmonary vascular impairment^ (combined with a component asthma)

Table 3: Cardiopulmonary responses to exercise in PPES patients *(continued)*

	Peak VO2 (% of pred)	Peak HR (% of pred)	Peak O2 pulse (% of pred)	Peak SpO2*	VE/MVV x 100	VE/VCO2 at AT	Peak Vd/VT	Peak p(A-a)O2 (kPa)	Unresolved thrombi and/or persistent perfusion defects#	Interpretation cardiopulmonary response
No. 33	83	58	143	98	53%	39,4			-	Pulmonary vascular impairment and cardiovascular impairment^
No. 34	105	106	99	97	42%	28,7		3,82	-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 35	85	97	89	99	49%	31,1			-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 36	74	70	107	96		27,5			-	Cardiovascular impairment^
No. 37	88	96	135						-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 38	77	86	90	100	58%	31,5			-	Cardiovascular impairment^
No. 39	77	77	100	100	46%	25	6	1,85	-	Cardiovascular impairment^
No. 40	81	74	110	100	33%	29,5			-	Cardiovascular impairment^
No. 41	104	98	106	98	69%	26,6	17	3,77	-	No cardiovascular, respiratory or pulmonary vascular impairment
No. 42	95	80	118	96	61%	35	19	3,04	-	Pulmonary vascular impairment^
No. 43	59	79	74	96	44%	48			-	Pulmonary vascular and cardiovascular impairment^
No. 44	93	93	80	92	88%	35,8		5,35	-	Pulmonary vascular and cardiovascular impairment^
No. 45	114	91	126	98	57%	23,3	12		-	No cardiovascular, respiratory or pulmonary vascular impairment

Note:

* Peripheral oxygen saturation is mentioned given lack of arterial blood gases in the majority of patients.

\# Unresolved thrombi according to CTPA assessment and/or perfusion defects based on V/Q scan.

^ Patients with insufficient cardiopulmonary responses as determined by CPET despite the absence of objectified persistent vascular occlusions on CTPA and/or V/Q scan.

Abbreviations: VO2, oxygen uptake, pred, predicted; HR, heart rate; O2 pulse, oxygen consumed per heart rate; SpO2, arterial oxygen saturation; VE/MVV, ventilatory reserve; VE/VCO2, ventilatory equivalent for carbon dioxide; AT, anaerobic threshold; Vd/VT, dead-space fraction; p(A-a)O2, alveolar-arterial gradient; Y, yes; CTEPH, chronic thromboembolic pulmonary hypertension.

12

Rehabilitation program

Our personalized 12-week rehabilitation program was completed by 27 patients, of whom 17 were female (63%) and mean age was 51 years (SD 14). At baseline, PEmb-QoL score was median 15 points (IQR 12 to 17) whereas the median CIS score was above the cut-off value for problematic fatigue (≥76): 93 (IQR 76 to 104).[63] HADS anxiety and depression scores exceeded the cut-off value of ≥8.0 points in three and four patients, respectively, indicating a possible anxiety or depressive disorder before start of the rehabilitation program. Median score for anxiety was 4.0 points (IQR 2.0 to 7.0), and for depression 6.0 points (IQR 3.0 to 8.0). Supervised training sessions were provided twice a week in 23 participants, and three times a week in 4 participants since full supervision in exercise training was required in these patients. Additional counselling was provided by a social worker in 24 (89%), a dietician in 19 (70%), occupational therapist in 17 (63%), and a psychologist in 15 (56%) patients. Two patients underwent smoking cessation counselling (7.4%), of whom one quitted smoking.

The duration of the rehabilitation program was median 13 weeks (IQR 11 to 16). Peak power output during the first versus the last training session was median 65 Watts (IQR 40 to 90) versus 75 Watts (IQR 40 to 135) with a median difference of 20 Watts (IQR 5.0 to 40; p=0.001). Quality of life was improved after rehabilitation with a median difference of 3.9 points (IQR -6.2 to -1.2; p<0.001) on the PEmb-Qol total score (**Table 4**). Changes in individual dimensions of the Pemb-QoL questionnaire are displayed in **Fig 2.** The burden of fatigue decreased with a median difference of 16 points on the CIS score (-39 to -3.5; p=0.003), reflecting statistically relevant improvement. Lower burden on both anxiety and depression domains of the HADS were reported (median difference 1.0 point, IQR -2.0 to 1.0 for each) with no improvement (p=0.19 and p=0.096), respectively (**Table 4**).

Moderate or severe functional limitations (PVFS scale grade ≥3) were present in 18 of 27 (67%) patients before rehabilitation, and in 7/27 (26%) at post-rehabilitation assessment, which is reflected by an overall improvement on the PVFS scale (p<0.001; **Fig 3**). Fourteen patients (52%) improved one grade on the PVFS scale and four patients (15%) improved two grades. Functional status remained unchanged in 8 patients (30%), whereas the remaining patient had a decline of one grade (3.7%). Importantly, while closely monitoring safety during the rehabilitation program, no thromboembolic or cardiac complications were observed besides one patient with new-onset atrial fibrillation.

Table 4: Patient-reported outcome measures

Questionnaire[#]	Available records	Median value before start of the rehabilitation program (IQR)	Median value after completing the rehabilitation program (IQR)	Median of differences (IQR)	P value*	MCID
PEmb-QoL (range 0-27 points)	23	15 (12 to 17)	11 (8.7 to 13)	-3.9 (-6.2 to -1.2)	<0.001	15 [61]
CIS (range 20-140 points)	18	93 (76 to 104)	67 (53 to 85)	-16 (-39 to -3.5)	0.003	N.A.
HADS anxiety (range 0-21 points)	19	4.0 (2.0 to 7.0)	4.0 (1.0 to 6.0)	-1.0 (-2.0 to 1.0)	0.189	1.6 (validated in COPD patients) [62]
HADS depression (range 0-21 points)	19	6.0 (3.0 to 8.0)	4.0 (2.0 to 6.0)	-1.0 (-2.0 to 1.0)	0.096	1.6 (validated in COPD patients) [62]

Note:

[#] *Lower scores indicate better self-reported quality of life (PEmb-QoL), less fatigue (CIS), or a lower burden of anxiety/depression (HADS).*

* *Wilcoxon signed rank test.*

Abbreviations: IQR, interquartile range; MCID, minimal clinically important difference; PEmb-QoL, PE-specific Quality of Life; CIS, Checklist Individual Strength-Fatigue; N.A., not available; HADS, Hospital Anxiety and Depression Scale.

12

PEmb-QoL before and after rehabilitation

Median before — Median after

Frequency of complaints

Emotional complaints

ADL limitations

Intensity of complaints

Work-related problems

Social limitations

Figure 2: Radar chart representing the change in all dimensions of the PEmb-Qol Questionnaire before and after the rehabilitation program (n=22)
Note: Lower scores indicate better quality of life.
Abbreviations: ADL, activities of daily living.

Before rehabilitation

PVFS Scale grade 4: 1 patients

Grade 3: 7 patients

PVFS Scale grade 3: 17 patients

Grade 2: 11 patients

PVFS Scale grade 2: 9 patients

Grade 1: 9 patients

After rehabilitation

Figure 3: Assignments of the post-VTE functional status scale grades before and after completing the 12-week pulmonary rehabilitation program (n=27)
Note: The width of lines in the figure are proportional to the flow rate.

DISCUSSION

This study demonstrates that insufficient cardiopulmonary responses to exercise are common among patients who suffer from the PPES, which is not limited to patients with persistent vascular occlusions. Exercise limitation was consistent with pulmonary vascular and/or cardiovascular impairment rather than respiratory impairment in all CTEPH patients, and also in more than half of non-CTEPH cases. A personalized 12-week rehabilitation program in patients with PPES in whom CTEPH and CTEPD suitable for PEA or BPA were ruled out, appeared to improve the training intensity, the PE-specific quality of life as well as the burden of fatigue. Functional status in patients' daily lives improved as well during the rehabilitation program. During the program, one patient was diagnosed with new-onset with atrial fibrillation, no other complications occurred.

Persistent thrombotic obstruction of pulmonary arteries was identified in about half of the non-CTEPH cases. However, increased dead-space ventilation or cardiovascular impairment was not observed in all of these patients. This illustrates the heterogeneous nature of physiological etiologies explaining exertional dyspnea in this patient group. The lack of correlation between reduced exercise capacity and imaging abnormalities in our and previous studies further suggests a multifactorial etiology rather than vascular disease in pulmonary arteries as only physiological determinant of post-PE dyspnea.[64] This study was not designed to identify deconditioning since clear diagnostic criteria are lacking. Therefore, the prevalence of deconditioning may be underestimated, also because alternative reasons for exercise limitation might be predominant. An incremental symptom-limited CPET is the recommended tool to comprehensively evaluate cardiovascular, ventilatory and peripheral metabolism responses in case of exertional dyspnea.[51,52] As such, non-invasive differentiation between mechanisms limiting exercise in PPES can be made.[65] In a Canadian prospective cohort study, the majority (87.5%) of patients with an abnormal 12-month CPET after their first episode of PE had deconditioning, 12.5% were classified to have ventilatory impairment and none were considered to have cardiovascular impairment.[19,20] Of note, this was an unselected PE population with relatively low-risk PE patients. A recent observational study including 40 patients with PPES revealed increased dead-space ventilation and/or decreased stroke volume reserve in up to 65% after 90 days of anticoagulant therapy.[66] Importantly, given the absence of unambiguous clinical algorithms for interpreting cardiopulmonary responses to exercise, some phenotypes of exercise intolerance overlap. As such, CPET mainly functions as a first means of identifying patterns rather than making a clear distinction between different causes. Taking into account our results, we argue that rehabilitation is a safe and promising approach that is mainly valuable in a population of adequately selected PE patients suffering from persistent dyspnea. This is fueled by a recent randomized trial in which an 8-week home-based exercise program was initiated

12

shortly after acute PE regardless of symptoms or pre-existing physical fitness.[31] Although this physiotherapist-guided program proved to be safe, the predefined criteria for efficacy have not been met. A currently ongoing randomized study evaluates whether a rehabilitation program improves exercise capacity in PPES patients (NCT03405480). Speculating, exercise training might also contribute to functional improvements in PPES patients treated with surgical, angioplasty or PH targeted therapy. Further randomized studies are needed to define criteria for adequate selection of particular PE patients who will likely benefit most from a rehabilitation program.

Strengths of our study include the standardized diagnostic work-up in all patients including pulmonary perfusion imaging, CPET and echocardiography in all patients, as well as the application of a state-of-the art supervised rehabilitation program.[42] Limitations include its relatively small sample size, the single-centre design and the likely selection bias leading to an enriched CTEPH prevalence in the study population due to referral from elsewhere to our unique 'post-PE syndrome clinic'. Therefore, the proportion of CTEPH versus CTEPD is probably not representative. Moreover, since pulmonary angiography was performed in case of suspected CTEPH only, i.e. in those patients with intermediate or high probability of CTEPH based on echocardiography, we cannot state with complete certainty that none of the other patients with persistent perfusion defects actually had CTEPH. Also, the observational nature of our study without a control group hinders to reliably quantify the full effect of a rehabilitation program compared to standard recovery. Interestingly, most study patients also received other types of allied healthcare, which may have contributed to an improvement in the functional status, a better quality of life and reduction in fatigue. However, previous prospective studies have shown limited improvement in the natural course of acute PE, especially when no rehabilitation program is offered. For example, a recent German cohort study following 620 PE patients showed that quality of life using the PEmb-QoL score improved between 3- and 12-month follow-up, but the MCID of 15 points was only attained in 118 patients (19%).[67] Of note, this MCID was obtained in a small selected cohort of 82 patients, which may have limited its generalizability.[61] Lastly, limitations of the pre-post study design are known and includes the lack of clear causality of the intervention on the observed changes, also due to unexpected temporal changes, regression to the mean, testing threat, and non-specific effects of the intervention.

In summary, insufficient cardiopulmonary responses to exercise seem to play an important role in the etiology of exertional dyspnea and functional limitations after acute PE, and was independent of persistent perfusion defects in the studied cohort. Our data suggest that offering a personalized pulmonary rehabilitation program to patients with PPES not otherwise treated is safe and promising given the observed improvement in patient-relevant outcomes. Randomized studies are nonetheless

required to validate our findings and to further determine which PPES patients benefit most from rehabilitation.

12

REFERENCES

1. Sista AK, Miller LE, Kahn SR, Kline JA. Persistent right ventricular dysfunction, functional capacity limitation, exercise intolerance, and quality of life impairment following pulmonary embolism: Systematic review with meta-analysis. Vascular Medicine 2017; 22(1): 37-43.
2. Klok FA, Barco S. Follow-up after acute Pulmonary Embolism. Hamostaseologie 2018; 38(1): 22-32.
3. Delcroix M, Torbicki A, Gopalan D, et al. ERS Statement on Chronic Thromboembolic Pulmonary Hypertension. European Respiratory Journal 2021;57(6):2002828.
4. Boon GJAM, Bogaard HJ, Klok FA. Essential aspects of the follow-up after acute pulmonary embolism: An illustrated review. Research and Practice in Thrombosis and Haemostasis 2020; 4(6): 958-68.
5. Klok FA, van Kralingen KW, van Dijk AP, Heyning FH, Vliegen HW, Huisman MV. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respiratory Medicine 2010; 104(11): 1744-9.
6. Huisman MV, Barco S, Cannegieter SC, et al. Pulmonary embolism. Nature Reviews Disease Primers 2018; 4: 18028.
7. Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Reviews 2014; 28(6): 221-6.
8. Sista AK, Klok FA. Late outcomes of pulmonary embolism: The post-PE syndrome. Thrombosis Research 2018; 164: 157-62.
9. Tavoly M, Wik HS, Sirnes PA, et al. The impact of post-pulmonary embolism syndrome and its possible determinants. Thrombosis Research 2018; 171: 84-91.
10. Fernandes T, Planquette B, Sanchez O, Morris T. From Acute to Chronic Thromboembolic Disease. Annals of the American Thoracic Society 2016; 13 Suppl 3: S207-14.
11. Boon GJAM, Huisman MV, Klok FA. Determinants and Management of the Post-Pulmonary Embolism Syndrome. Seminars in Respiratory and Critical Care Medicine 2021; 42(2): 299-307.
12. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal 2017; 49(2): 1601792.
13. Pugliese SC, Kawut SM. The Post-Pulmonary Embolism Syndrome: Real or Ruse? Annals of the American Thoracic Society 2019; 16(7): 811-4.
14. Klok FA, Delcroix M, Bogaard HJ. Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism. Journal of Thrombosis and Haemostasis 2018; 16(6): 1040-51.
15. Held M, Kolb P, Grun M, et al. Functional Characterization of Patients with Chronic Thromboembolic Disease. Respiration 2016; 91(6): 503-9.
16. Claeys M, Claessen G, La Gerche A, et al. Impaired Cardiac Reserve and Abnormal Vascular Load Limit Exercise Capacity in Chronic Thromboembolic Disease. JACC Cardiovascular Imaging 2019; 12(8 Pt 1): 1444-56.
17. Stevinson BG, Hernandez-Nino J, Rose G, Kline JA. Echocardiographic and functional cardiopulmonary problems 6 months after first-time pulmonary embolism in previously healthy patients. European Heart Journal 2007; 28(20): 2517-24.
18. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary

embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009; 136(5): 1202-10.

19. Kahn SR, Akaberi A, Granton JT, et al. Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. American Journal of Medicine. 2017;130(8):990.e9-.e21.

20. Kahn SR, Hirsch AM, Akaberi A, et al. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. Chest 2017; 151(5): 1058-68.

21. Hunter R, Noble S, Lewis S, Bennett P. Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community. BMJ Open 2019; 9(2): e024805.

22. Kirchberger I, Ruile S, Linseisen J, Haberl S, Meisinger C, Berghaus TM. The lived experience with pulmonary embolism: A qualitative study using focus groups. Respiratory Medicine 2020; 167: 105978.

23. Klok FA, Couturaud F, Delcroix M, Humbert M. Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal 2020;55(6):2000189.

24. Klok FA, van Kralingen KW, van Dijk AP, et al. Quality of life in long-term survivors of acute pulmonary embolism. Chest 2010; 138(6): 1432-40.

25. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Heart Journal 2016; 69(2): 177.

26. Inami T, Kataoka M, Kikuchi H, Goda A, Satoh T. Balloon pulmonary angioplasty for symptomatic chronic thromboembolic disease without pulmonary hypertension at rest. International Journal of Cardiology 2019; 289: 116-8.

27. Wiedenroth CB, Olsson KM, Guth S, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulmonary Circulation 2018; 8(1): 2045893217753122.

28. Olgun Yildizeli S, Kepez A, Tas S, et al. Pulmonary endarterectomy for patients with chronic thromboembolic disease. Anatolian Journal of Cardiology 2018; 19(4): 273-8.

29. Taboada D, Pepke-Zaba J, Jenkins DP, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. European Respiratory Journal 2014; 44(6): 1635-45.

30. Cires-Drouet RS, Mayorga-Carlin M, Toursavadkohi S, et al. Safety of exercise therapy after acute pulmonary embolism. Phlebology 2020: 268355520946625.

31. Rolving N, Brocki BC, Bloch-Nielsen JR, et al. Effect of a Physiotherapist-Guided Home-Based Exercise Intervention on Physical Capacity and Patient-Reported Outcomes Among Patients With Acute Pulmonary Embolism: A Randomized Clinical Trial. JAMA Network Open 2020; 3(2): e200064.

32. Nopp S, Klok FA, Moik F, et al. Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism. Journal of Clinical Medicine 2020; 9(6).

33. Amoury M, Noack F, Kleeberg K, et al. Prognosis of patients with pulmonary embolism after rehabilitation. Vascular Health and Risk Management 2018; 14: 183-7.

34. Noack F, Schmidt B, Amoury M, et al. Feasibility and safety of rehabilitation after venous thromboembolism. Vascular Health and Risk Management 2015; 11: 397-401.

35. Lakoski SG, Savage PD, Berkman AM, et al. The safety and efficacy of early-initiation exercise training after acute venous thromboembolism: a randomized clinical trial. Journal of Thrombosis and Haemostasis 2015; 13(7): 1238-44.

12

36. Nagel C, Nasereddin M, Benjamin N, et al. Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study. Respiration 2020: 1-12.

37. Grunig E, Eichstaedt C, Barbera JA, et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal 2019; 53(2).

38. Koudstaal T, Wapenaar M, van Ranst D, et al. The Effects of a 10-wk Outpatient Pulmonary Rehabilitation Program on Exercise Performance, Muscle Strength, Soluble Biomarkers, and Quality of Life in Patients With Pulmonary Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention 2019; 39(6): 397-402.

39. Morris NR, Kermeen FD, Holland AE. Exercise-based rehabilitation programmes for pulmonary hypertension. The Cochrane Database of Systematic Reviews 2017; 1: CD011285.

40. Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. European Heart Journal 2016; 37(1): 35-44.

41. Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal 2013; 34(38): 2949-3003.

42. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine 2013; 188(8): e13-64.

43. Huisman MV, Klok FA. How I diagnose acute pulmonary embolism. Blood 2013; 121(22): 4443-8.

44. Huisman MV, Klok FA. Diagnostic management of clinically suspected acute pulmonary embolism. Journal of Thrombosis and Haemostasis 2009; 7 Suppl 1: 312-7.

45. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Haemostasis 2013; 11(3): 412-22.

46. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Heart Journal 2016; 69(2): 177.

47. American College of Sports Medicine, Riebe D, Ehrman JK, Liguori G, Magal M. ACSM's guidelines for exercise testing and prescription; 2018.

48. Wasserman K. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 5th ed. ed: Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, c2012.; 2012.

49. American Thoracic S, American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2003; 167(2): 211-77.

50. Campbell SC. A comparison of the maximum voluntary ventilation with the forced expiratory volume in one second: an assessment of subject cooperation. Journal of Occupational Medicine 1982; 24(7): 531-3.

51. Radtke T, Crook S, Kaltsakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. European Respiratory Review 2019; 28(154).

52. Herdy AH, Ritt LE, Stein R, et al. Cardiopulmonary Exercise Test: Background, Applicability and Interpretation. Arquivos Brasileiros de Cardiologia 2016; 107(5): 467-81.

53. Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. European Respiratory Journal 2017; 49(1).

54. Cohn DM, Nelis EA, Busweiler LA, Kaptein AA, Middeldorp S. Quality of life after pulmonary embolism: the development of the PEmb-QoL questionnaire. Journal of Thrombosis and Haemostasis 2009; 7(6): 1044-6.

55. Klok FA, Cohn DM, Middeldorp S, et al. Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire. Journal of Thrombosis and Haemostasis 2010; 8(3): 523-32.

56. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. Journal of Psychosomatic Research 1994; 38(5): 383-92.

57. Snaith RP. The Hospital Anxiety And Depression Scale. Health and Quality of Life Outcomes 2003; 1: 29.

58. Klok FA, Barco S, Siegerink B. Measuring functional limitations after venous thromboembolism: A call to action. Thrombosis Research 2019; 178: 59-62.

59. Boon GJAM, Barco S, Bertoletti L, et al. Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. Thrombosis Research 2020; 190: 45-51.

60. Machado FVC, Meys R, Delbressine JM, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health and Quality of Life Outcomes 2021; 19(1): 40.

61. Akaberi A, Klok FA, Cohn DM, Hirsch A, Granton J, Kahn SR. Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life. Journal of Thrombosis and Haemostasis 2018; 2018 Dec;16(12):2454-2461.

62. Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health and Quality of Life Outcomes 2008; 6(1): 46.

63. De Vries J, Michielsen HJ, Van Heck GL. Assessment of fatigue among working people: a comparison of six questionnaires. Occupational and Environmental Medicine 2003; 60 Suppl 1(Suppl 1): i10-5.

64. Albaghdadi MS, Dudzinski DM, Giordano N, et al. Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. Journal of the American Heart Association 2018; 7(5).

65. Guazzi M, Adams V, Conraads V, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012; 126(18): 2261-74.

66. Fernandes TM, Alotaibi M, Strozza DM, et al. Dyspnea Postpulmonary Embolism From Physiological Dead Space Proportion and Stroke Volume Defects During Exercise. Chest 2020; 157(4): 936-44.

67. Valerio L, Barco S, Jankowski M, et al. Quality of Life Three and Twelve Months after Acute Pulmonary Embolism: Analysis from a Prospective Multicenter Cohort Study. Chest 2021; 159(6):2428-2438.

12

Appendix A: Group and individual sessions during 12-week pulmonary rehabilitation program

Type of sessions	Frequency
<u>Group sessions</u>	
Endurance exercise training (30-40 minutes): The endurance training was performed on a stationary cycle ergometer and/or a treadmill, and comprised endurance and/or interval exercise. Aim: each training was targeted at 70 to 80% of patients' individual maximum heart rate, which was routinely checked by the physiotherapist supervising the training.	Twice-weekly
Strength exercise training (30 minutes): Strength training was performed using medical fitness equipment. Aim: either improving absolute muscle strength or improvement in muscle endurance, depending on the outcomes of initial assessment and individual goals. For improvement of strength, patients trained at 75% of their one repetition maximum (1RM), performing 3 series of 8 repetitions. When training muscle endurance, 2 series of 15 repetitions at 65% of the 1RM were performed.	
Third training at home (60 minutes): Patients were instructed to exercise at home, targeting the same intensity as the supervised training sessions.	Once a week (after two weeks)
Information sessions: Related to several subjects including relaxation exercises, education about exercising or adapting to the disease and functional limitations.	Depending on the number of assigned sessions
<u>Individual sessions</u>	
Initial assessment: • Interviews with a pulmonologist, physiotherapist and social worker • Optional: interviews with occupational therapist, dietician, psychologist • Questionnaires • Steep ramp test • Measurements of m. quadriceps force using a handheld dynamometer and hand grip force using a hand dynamometer	Once, before starting the actual program
Pulmonologist consultation (15-60 minutes): Related to acute pulmonary problems, rehabilitation-progress, medication and lifestyle changes.	At least three consultations
Physiotherapist consultation (15-30 minutes): Related to physical activity at home, how to maintain fitness after completing the program.	At least four consultations
Social worker consultation (45-60 minutes): Related to among other smoking cessation and social support.	If applicable
Occupational therapist consultation: Aimed at improving activities in daily living using ergonomic principles and energy conservation/distribution.	If applicable
Dietician consultation: Depending on a patient's body weight, BMI, comorbidities and requests for help.	If applicable
Psychologist consultation: Conversations and, if relevant, treatment such as cognitive behavioural therapy or EMDR.	If applicable

Appendix B: Post-VTE Functional Status (PVFS) Scale

PVFS scale grade		Description
0	No functional limitations	No symptoms, pain, or anxiety.
1	Negligible functional limitations	All usual duties/activities at home or at work can be carried out at the same level of intensity, despite some symptoms, pain, or anxiety.
2	Slight functional limitations	Usual duties/activities at home or at work are carried out at a lower level of intensity or are occasionally avoided due to symptoms, pain, or anxiety.
3	Moderate functional limitations	Usual duties/activities at home or at work have been structurally modified (reduced) due to symptoms, pain, or anxiety.
4	Severe functional limitations	Assistance needed in activities of daily living due to symptoms, pain, or anxiety: nursing care and attention are required.
D	Death	-

12